GE Healthcare launches automation software for CAR-T manufacturing

By Vassia Barba

- Last updated on GMT

(Image: Getty/cgtoolbox)
(Image: Getty/cgtoolbox)

Related tags Ge healthcare GE Healthcare Life Sciences CAR-T Cell therapy T cells

GE Healthcare tops its C-Pro cell processing system with SpinOculation, an automation software that enables closed T cells transduction at the preferred volume and concentration.

The newly available service, known as SpinOculation C-Pro Protocol Software, was designed to run on the company’s Sepax C-Pro Cell Processing System, and is expected to facilitate and accelerate the cell transduction step, during the manufacturing of chimeric antigen receptor (CAR)-T therapies.

Catarina Flyborg, GM of cell and gene therapy at GE Healthcare, commented that the launch of the service answers a need for advanced technologies to support cell and gene therapy manufacturing, since it can simplify a ‘critical’ step in the cell therapy workflow.

The software automates the transduction phase of the process, which so far has been done manually. Moreover, it enables users to choose the volume and cell concentration from the steps of cell preparation through to transduction and final resuspension.

According to GE Healthcare, automation of the process means enhanced security and sterility of the end product, reduced manipulations and time required, as well as maintaining cell viability and virus stability.

A spokesperson for the company told us that GE Healthcare is also looking to automate further parts of the process, aiming for improved efficiency and speed.

SpinOculation is the only stand-alone software solution on the market for this purpose, providing a closed, reproducible and traceable operative service.

Additionally, according to the company, the technology has the potential to optimize performance through adjustments of the open system parameters by the user.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars